Michel Sadelain, Carl June receive 2024 Breakthrough Prize in Life Sciences

Michel Sadelain

Carl June

Michel Sadelain, of Memorial Sloan Kettering Cancer Center, and Carl June, of University of Pennsylvania, are two of the recipients of the 2024 Breakthrough Prize in Life Sciences for the development of chimeric antigen receptor T-cell immunotherapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Scientists uncover protein that helps cancer cells dodge CAR T-cell therapy

Scientists at City of Hope identified a protein that could help prevent CAR T-cell therapy antigen escape. The research, published in the journal Cell, could lead to more personalized therapies that improve cancer patients’ survival.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

Researchers from City of Hope, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, the University of Pennsylvania, and NIH have developed a way to add features to T cells to help them overcome mechanisms of chimeric antigen receptor T-cell therapy resistance. The new system is outlined in a paper published in Nature Biomedical Engineering.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

Nektar Therapeutics announced results of its phase II proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma at the 66th ASH Annual Meeting and Exposition in San Diego.

December 13, 2024

Vol.50 No.46

Clinical Roundup

CAR T-cell therapy obe-cel demonstrates high response rates in advanced B-cell ALL

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia who were treated with the novel anti-CD19 chimeric antigen receptor T-cell therapy, obecabtagene autoleucel, experienced high response rates and most did not need a subsequent stem cell transplant, according to results from the phase Ib/II FELIX trial co-led by researchers at the University of Texas MD Anderson Cancer Center.

December 06, 2024

Vol.50 No.45

Clinical Roundup

CAR T cells armed with IL-15 show promise in treating solid cancers

A study published in the journal Nature reports results of the first-in-human phase I clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3. Researchers at Baylor College of Medicine and Texas Children’s Cancer Center led the study, which tested chimeric antigen receptor T cells enhanced with the protein interleukin-15.

December 06, 2024

Vol.50 No.45

In Brief

Robert Schnoll named John H. Glick, MD Professor in Cancer Research at Penn Medicine

Robert Schnoll, Penn Medicine’s Abramson Cancer Center’s associate director for population science, was named the John H. Glick, MD Professor in Cancer Research. Schnoll is also the director of the Center for Interdisciplinary Research on Nicotine Addiction, a senior fellow in the Penn Center for Public Health, and co-director of the Community Research and Engagement Core at the Penn Center for AIDS Research.

November 22, 2024

Vol.50 No.44

Michel Sadelain, Carl June receive 2024 Breakthrough Prize in Life Sciences

YOU MAY BE INTERESTED IN

Scientists uncover protein that helps cancer cells dodge CAR T-cell therapy

Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

CAR T-cell therapy obe-cel demonstrates high response rates in advanced B-cell ALL

CAR T cells armed with IL-15 show promise in treating solid cancers

Robert Schnoll named John H. Glick, MD Professor in Cancer Research at Penn Medicine

Renew today!

Subscriber content

Never miss an issue!

Login